Article Text

Download PDFPDF
CD138/syndecan–1 in pancreatic solid and pseudopapillary neoplasms
  1. Adriana Handra-Luca1,2
  1. 1 Depatment of Pathology, APHP GHU Avicenne, Bobigny, France
  2. 2 UFR de Santé Médecine et Biologie Humaine, Universite Paris Nord, Bobigny, France
  1. Correspondence to Dr Adriana Handra-Luca, Service d'Anatomie pathologique APHP GHU Avicenne, Universite Paris Nord, Bobigny 93009, France; adriana.handra-luca{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Solid and pseudopapillary neoplasms (SPNs) are rare tumours, their histogenesis is still a matter of debate. These tumours are reported to express CD-type proteins such as CD10, CD56 and CD99.1 We have recently observed another CD-type protein expression, that of CD138/syndecan-1, frequently used to point out a plasma cell differentiation.

The antibody used for the immunohistochemistry technique was the clone MI15 (IgG1 class) (Leica Biosystems, PA0088) reacting with human CD138 (immunogen: mixture of U266 and XG-1 human myeloma cell lines). The Leica Biosystems Bond III automated system has been used. Heat-induced epitope retrieval was performed with the citrate-based Bond Epitope Refine Solution-1 (30 min/mn). The Bond III Polymer Refine Detection system has been used as follows: …

View Full Text


  • Handling editor Dhirendra Govender.

  • Contributors AH-L: analysis of data and manuscript writing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.